Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1932989 | 0.98 | NPSR1 (0.39) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| Bromide SCHEMBL9989922 | 0.98 | NPSR1 (0.39) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| SCHEMBL2827416 | 0.91 | NPSR1 (0.38) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| SCHEMBL21618356 | 0.91 | NPSR1 (0.38) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| SCHEMBL2445606 | 0.89 | NPSR1 (0.46) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| Hydrochloric Acid SCHEMBL19837689 | 0.89 | NPSR1 (0.36) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| SCHEMBL10151700 | 0.83 | NPSR1 (0.37) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| SCHEMBL4093471 | 0.83 | PKM (0.39) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| SCHEMBL22276283 | 0.82 | NPSR1 (0.35) | NPSR1CHRM1HSD11B1LMNAADORA2A | |
| SCHEMBL19766520 | 0.82 | NPSR1 (0.37) | NPSR1LMNACYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697412-B1 | A COMPOUND FOR TREATING OSTEOARTHRITIS | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-02-25 | — | — | EP | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-3814358-B1 | METHOD FOR PREPARING 2-INDOLINOSPIRONE COMPOUNDS AND INTERMEDIATES THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2025-09-03 | — | — | EP | disclosed |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2025-06-19 | — | — | US | disclosed |
| US-20250179023-A1 | HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-119923393-A | Methyltransferase inhibitors and uses thereof | 上海赛岚生物科技有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025048759-A1 | BENZIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS | ICOSYN THERAPEUTICS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-03-06 | — | — | WO | disclosed |
| EP-4491617-A1 | HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-01-15 | — | — | EP | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | NPSR1 1145/4885CHRM1 4440/4885HSD11B1 2054/4885 |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | HPGDS, PTGIS, HPGD | NPSR1 1640/4885CHRM1 4335/4885HSD11B1 20/4885 |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | NPSR1 4083/4885CHRM1 4441/4885HSD11B1 236/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | NPSR1 2352/4885CHRM1 4795/4885HSD11B1 1268/4885 |
| US-20250179023-A1 | HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | NPSR1 3767/4885CHRM1 3984/4885HSD11B1 37/4885 |
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | EZH2, DOT1L, EHMT1 | NPSR1 3515/4885CHRM1 732/4885HSD11B1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.